Alerts will be sent to your verified email
Verify EmailCONCORDBIO
5
10
20
Balance sheet of Concord Biotech is strong.
It shouldn't have solvency or liquidity issues.
The net debt of Concord Biotech is decreasing.
Latest net debt of Concord Biotech is -₹19.04 Crs as of Sep-25.
This is less than Mar-25 when it was -₹1.97 Crs.
The profit is oscillating.
The profit of Concord Biotech is ₹319 Crs for TTM, ₹372 Crs for Mar 2025 and ₹308 Crs for Mar 2024.
The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Biotech latest dividend payout ratio is 30.12% and 3yr average dividend payout ratio is 29.86%
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Accounts Receivable